Kramer A - Search Results

1

Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design.

Li YR, Ochoa CJ, Zhu Y, Kramer A, Wilson M, Fang Y, Chen Y, Singh T, Di Bernardo G, Zhu E, Lee D, Moatamed NA, Bando J, Zhou JJ, Memarzadeh S, Yang L. Li YR, et al. Among authors: kramer a. iScience. 2023 Sep 19;26(10):107952. doi: 10.1016/j.isci.2023.107952. eCollection 2023 Oct 20. iScience. 2023. PMID: 37810241 Free PMC article.

2

Engineering stem cells for cancer immunotherapy.

Li YR, Zhou Y, Kramer A, Yang L. Li YR, et al. Among authors: kramer a. Trends Cancer. 2021 Dec;7(12):1059-1073. doi: 10.1016/j.trecan.2021.08.004. Epub 2021 Sep 1. Trends Cancer. 2021. PMID: 34479851 Review.

3

An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy.

Li YR, Yu Y, Kramer A, Hon R, Wilson M, Brown J, Yang L. Li YR, et al. Among authors: kramer a. Cells. 2022 May 8;11(9):1583. doi: 10.3390/cells11091583. Cells. 2022. PMID: 35563889 Free PMC article.

4

Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity.

Li YR, Brown J, Yu Y, Lee D, Zhou K, Dunn ZS, Hon R, Wilson M, Kramer A, Zhu Y, Fang Y, Yang L. Li YR, et al. Among authors: kramer a. Cancers (Basel). 2022 Jun 1;14(11):2749. doi: 10.3390/cancers14112749. Cancers (Basel). 2022. PMID: 35681730 Free PMC article.

5

Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors.

Li YR, Zhou Y, Wilson M, Kramer A, Hon R, Zhu Y, Fang Y, Yang L. Li YR, et al. Among authors: kramer a. Int J Mol Sci. 2022 Jul 7;23(14):7547. doi: 10.3390/ijms23147547. Int J Mol Sci. 2022. PMID: 35886891 Free PMC article.

6

Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers.

Li YR, Zeng S, Dunn ZS, Zhou Y, Li Z, Yu J, Wang YC, Ku J, Cook N, Kramer A, Yang L. Li YR, et al. Among authors: kramer a. iScience. 2022 Aug 6;25(9):104859. doi: 10.1016/j.isci.2022.104859. eCollection 2022 Sep 16. iScience. 2022. PMID: 36034226 Free PMC article.

7

Mucosal-associated invariant T cells for cancer immunotherapy.

Li YR, Zhou K, Wilson M, Kramer A, Zhu Y, Dawson N, Yang L. Li YR, et al. Among authors: kramer a. Mol Ther. 2023 Mar 1;31(3):631-646. doi: 10.1016/j.ymthe.2022.11.019. Epub 2022 Dec 5. Mol Ther. 2023. PMID: 36463401 Free PMC article. Review.

8

Graft-versus-Host Disease Modulation by Innate T Cells.

Fang Y, Zhu Y, Kramer A, Chen Y, Li YR, Yang L. Fang Y, et al. Among authors: kramer a. Int J Mol Sci. 2023 Feb 17;24(4):4084. doi: 10.3390/ijms24044084. Int J Mol Sci. 2023. PMID: 36835495 Free PMC article. Review.

9

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy.

Chen Y, Zhu Y, Kramer A, Fang Y, Wilson M, Li YR, Yang L. Chen Y, et al. Among authors: kramer a. Front Med (Lausanne). 2023 Mar 29;10:1135468. doi: 10.3389/fmed.2023.1135468. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37064017 Free PMC article. Review.

10

Human dopaminergic system in the exercise-cognition link.

Hou M, Herold F, Zhang Z, Ando S, Cheval B, Ludyga S, Erickson KI, Hillman CH, Yu Q, Liu-Ambrose T, Kuang J, Kramer AF, Chen Y, Costello JT, Chen C, Dupuy O, Pindus DM, McMorris T, Stiernman L, Zou L. Hou M, et al. Among authors: kramer af. Trends Mol Med. 2024 May 7:S1471-4914(24)00099-6. doi: 10.1016/j.molmed.2024.04.011. Online ahead of print. Trends Mol Med. 2024. PMID: 38719712

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,972 results

Search Page